Concord Drugs Ltd vs Wanbury Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Concord Drugs Ltd is ₹ 85.04 as of 05 May 15:30 . The P/E Ratio of Concord Drugs Ltd changed from 15.9 on March 2022 to 91.4 on March 2025 . This represents a CAGR of 54.84% over 4 yearsThe P/E Ratio of Wanbury Ltd changed from 3.4 on March 2022 to 25.2 on March 2025 . This represents a CAGR of 65.00% over 4 years The Market Cap of Concord Drugs Ltd changed from ₹ 25.36 crore on March 2022 to ₹ 31.08 crore on March 2025 . This represents a CAGR of 5.22% over 4 yearsThe Market Cap of Wanbury Ltd changed from ₹ 207.5 crore on March 2021 to ₹ 768.96 crore on March 2025 . This represents a CAGR of 29.95% over 5 years The revenue of Concord Drugs Ltd for the Dec '25 is ₹ 16.99 crore as compare to the Sep '25 revenue of ₹ 10.28 crore. This represent the growth of 65.27% The revenue of Wanbury Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Concord Drugs Ltd for the Dec '25 is ₹ 0.94 crore as compare to the Sep '25 ebitda of ₹ 1.1 crore. This represent the decline of -14.55% The ebitda of Wanbury Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Concord Drugs Ltd changed from ₹ 0.03 crore to ₹ 0.22 crore over 7 quarters. This represents a CAGR of 212.22% The net profit of Wanbury Ltd changed from ₹ 1.04 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of -100.00% The Dividend Payout of Concord Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Wanbury Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Concord Drugs Ltd

Concord Drugs Limited, established in 1995, is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenterals, Dry Syrup powder) ,Tissue Bio-Adhesive, tablets, capsules and ophthalmic preparations and Ready-to-fill Pellets. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved.
The Company has two manufacturing facilities license issued by The Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad.
State of the art technology having dedicated manufacturing facilities for Liquid Injections, Dry powder Injections and Ready-to-fill Pellets ensures the highest level of process integrity and product quality. The Company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing.

About Wanbury Ltd

Wanbury Limited, formerly known Pearl Organics Limited was incorporated in August, 1988.
The Company attained its present name in September 2004.
The Company is engaged in the business of pharmaceutical and related activities, including research. The company has established its first plant in the year 1992 in Tarapur for manufacturing APIs.
In 1995, the Company acquired plant of Brij Chemicals Pvt Ltd at Patalganga.
In 1996, it entered into a strategic alliance with Wyckoff Chemicals to manufacture its API in US. In 2007-08, the merger of Doctors Organic Chemicals Limited (DOCL) with the Company became effective from 1st April, 2007.

FAQs for the comparison of Concord Drugs Ltd and Wanbury Ltd

Which company has a larger market capitalization, Concord Drugs Ltd or Wanbury Ltd?

Market cap of Concord Drugs Ltd is 110 Cr while Market cap of Wanbury Ltd is 884 Cr

What are the key factors driving the stock performance of Concord Drugs Ltd and Wanbury Ltd?

The stock performance of Concord Drugs Ltd and Wanbury Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Concord Drugs Ltd and Wanbury Ltd?

As of May 5, 2026, the Concord Drugs Ltd stock price is INR ₹84.24. On the other hand, Wanbury Ltd stock price is INR ₹253.05.

How do dividend payouts of Concord Drugs Ltd and Wanbury Ltd compare?

To compare the dividend payouts of Concord Drugs Ltd and Wanbury Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.